The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis

BACKGROUND: Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator that has led to large benefits in lung function, pulmonary exacerbation rates, and respiratory symptoms. Less is known about the effect of ETI on non-pulmonary symptoms. The objective of this study was to examine the changes in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Allgood, Sarah, Levy, Reena, Bubaris, Despina, Riekert, Kristin, Psoter, Kevin J., Lechtzin, Noah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559839/
https://www.ncbi.nlm.nih.gov/pubmed/37810077
http://dx.doi.org/10.1016/j.heliyon.2023.e20110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559839/
https://www.ncbi.nlm.nih.gov/pubmed/37810077
http://dx.doi.org/10.1016/j.heliyon.2023.e20110

Ejemplares similares